Glucotrack announced the completion of a second long-term preclinical study for its implantable continuous blood glucose monitor (CBGM).
The study further validates the CBGM’s sustained accuracy, the company says. It demonstrated a mean absolute relative difference (MARD) — a measurement of CGM accuracy — of 4.7% at day 90.
MARD measures the average difference between the CBGM device’s measurement and a reference measurement. Lower values indicate better performance.
Get the full story at our sister site, Drug Delivery Business News.
